TFF Pharmaceuticals, Inc. announced that the Company will present data from the Phase 2 trial of Voriconazole Inhalation Powder (TFF VORI) for the treatment of invasive pulmonary aspergillosis at the upcoming Advances Against Aspergillosis & Mucormycosis (AAAM) Conference, which will be held from January 25-27, 2024, in Milan, Italy. Data being presented at the AAAM Conference were first disclosed by the Company in December 2023. TFF Pharmaceuticals' proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits.

The TFF process is a particle engineering process designed to generate dry powder particles with advantages for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. TFF does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the formulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of TFF can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products.